S&CO Inc. Grows Position in Revolution Medicines, Inc. $RVMD

S&CO Inc. raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 54.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 34,171 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. S&CO Inc.’s holdings in Revolution Medicines were worth $2,721,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Indiana Trust & Investment Management Co purchased a new stake in shares of Revolution Medicines in the 4th quarter valued at about $32,000. Torren Management LLC purchased a new stake in shares of Revolution Medicines in the 4th quarter valued at about $33,000. Darwin Wealth Management LLC purchased a new stake in shares of Revolution Medicines in the 4th quarter valued at about $40,000. Allworth Financial LP raised its position in shares of Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock valued at $46,000 after buying an additional 210 shares in the last quarter. Finally, Signaturefd LLC raised its position in shares of Revolution Medicines by 33.1% during the 4th quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after buying an additional 163 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $145.66 on Friday. The stock has a market cap of $30.97 billion, a price-to-earnings ratio of -20.60 and a beta of 1.41. The stock’s 50-day moving average is $118.73 and its 200 day moving average is $98.02. Revolution Medicines, Inc. has a 1-year low of $34.00 and a 1-year high of $155.70. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the prior year, the firm posted ($1.13) EPS. On average, sell-side analysts anticipate that Revolution Medicines, Inc. will post -7.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RVMD. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Truist Financial upgraded shares of Revolution Medicines to a “strong-buy” rating in a research report on Monday, April 27th. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating on shares of Revolution Medicines in a research report on Wednesday, April 22nd. Finally, Piper Sandler raised their price objective on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines has an average rating of “Buy” and a consensus target price of $103.88.

Insider Buying and Selling

In related news, insider Lin Wei sold 2,073 shares of Revolution Medicines stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $206,222.04. Following the transaction, the insider owned 101,366 shares in the company, valued at $10,083,889.68. This trade represents a 2.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen Michael Kelsey sold 4,302 shares of Revolution Medicines stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $427,962.96. Following the completion of the transaction, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 184,592 shares of company stock worth $24,499,532 over the last 90 days. Insiders own 8.20% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.